Facebook
Twitter
LinkedIn
ForwardEPC 2023 Updates in Pulmonary Disease
The Eastern Pulmonary Conference (EPC) will plan and organize a CME meeting on clinical topics in Pulmonary Medicine. With didactic lectures, panel discussions and case presentations, EPC blends the interactivity characteristic of a small regional conference with the relevant information which improves the diagnostic accuracy and the effectiveness of treatments with practitioners who treat pulmonary diseases. Physicians, PAs and NPs are invited to attend.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Eastern Pulmonary Conference (EPC). The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 16.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 16.25 contact hours.
Target Audience
Practicing pulmonologists and allergists
Fellows in pulmonary training programs
Primary care physicians who care for pulmonary patients
Allied health professionals in the field of pulmonary
Learning Objectives
At the conclusion of this Activity learners should be able to…
• Understand the approach of classification of interstitial pneumonia using treatable traits.
• Learn the role of the pulmonologist in diagnosis and management of sleep disorder breathing.
• Understand how idiopathic pulmonary fibrosis affects sleep.
• Become familiar with the use of augmented intelligence and machine learning in reading chest radiographs and imaging.
• Understand what steps to take when biologic therapy is not resulting in effectiveness for severe asthma
• Learn the newest guidelines in the management of asthma and COPD.
• Recognize the current treatment modalities for rescue therapy and address non-genomic effects of steroids in eth management of asthma.
• Be familiar with the differential diagnosis and workup of patients with critical illnesses in pregnancy.
• Understand current literature on the obese asthma phenotype regarding pathogenesis and management.
• Understand how phenotypes of COPD predict therapeutic responses in the management of COPD.
• Address how comorbidities effect COPD management.
• Become familiar with the importance of differential diagnosis in the management of pulmonary hypertension.
• Address the recent advances in the management of acute respiratory failure in the ICU.
• Identify the causes and therapeutic approaches to chronic cough.
• Explain the clinical presentations, treatments, and outcomes in adult non-CF bronchiectasis.
• Address how to diagnosis long COVID and what are our therapeutic options.
• Discuss the role of immunobiology in the pathophysiology and treatment of lung diseases.
Eastern Pulmonary Conference Meeting Program
Thursday, September 21, 2023 3:30 – 6:30 pm
Moderator: Rey Panettieri, MD
3:30 – 4:00 Pulmonary manifestations of immunodeficiency: How to assess
Antoine Azar, MD
4:00– 4:05 Q & A
4:05 – 5:05 PBL: A 50-year-old smoker with mild to moderate dyspnea on exercise
Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD,
Rey Panettieri, MD, William Corrao, MD
5:05 – 5:30 Something new, something old and …? New COPD guidelines: Relevance for the practicing pulmonologist
Nick Hanania, MD
5:30 – 5:55 COPD, smoke and mirrors (mimickers): Alpha-1 antitrypsin deficiency and bronchiectasis
Stephen Peters, MD
5:55 – 6:20 Unmasking the mystery of MAC infections: What every pulmonologist should know
Charles Daley, MD
6:20 – 6:30 Q & A
Adjourn
Friday, September 22, 2023 7:45 am – 2:45 pm
Moderator: Rey Panettieri, MD
7:45 – 8:15 Hocus POCUS: The ICU experience
Jinesh Mehta, MD
8:15 – 8:45 Sleep phenotypes: What’s new? Is it all about snoring?
Richard Millman, MD
8:45 – 8:55 Q & A
8:55 – 10:15 PBL: A 57-year-old man with progressively worsening dyspnea on exercise
Ray Davis, MD, Don Bukstein, MD, Rey Panettieri, MD,
Marilyn Glassberg, MD, Mario Castro, MD
10:15 – 11:00 Coffee Break: Visit Exhibits and Posters
11:00 – 11:20 What about orphans? ILD
Marilyn Glassberg, MD
11:20 – 11:40 Old scarring: Aging & ILD
Lesley Saketkoo, MD
11:40 – 12:00 A picture is worth 1000 words: ML/AI & ILD imaging
Bruno Hochhegger, MD
12:00 – 12:20 Sarcoidosis: New views for an ageless problem
Daniel Culver, MD
12:20 – 12:30 Q & A
Moderator: William Greisner, III, MD
1:25 – 1:55 Scarring and sleep?
Lisa Lancaster, MD
1:55 – 2:30 Stop the fluid? Management of malignant pleural effusion
Momen Wahidi, MD
2:30 – 2:45 Q & A
Adjourn
Saturday, September 23, 2023 7:45 am – 3:15 pm
Moderator: Russell Settipane, MD
7:45 – 8:15 Advances in the surgical management of complex lung diseases
Tiago Machuca, MD
8:15 – 8:45 Vessels and pressures: PAH update
James Klinger, MD
8:45 – 8:55 Q & A
8:55 – 10:15 PBL: A 51-year-old woman with frequent asthma exacerbations
Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD,
Rey Panettieri, MD, Mario Castro, MD
10:15 – 11:00 Coffee Break: Visit Exhibits and Posters
11:00 – 11:25 It’s not about T2! Low T2 asthma phenotype pathophysiology
Tom Casale, MD
11:25 – 11:50 What to do when there’s no eosinophils? Treatment of low T2 asthma phenotype
Mario Castro, MD
11:50 – 12:15 Let’s dilate! Novel bronchodilators for asthma management
Rey Panettieri, MD
12:15 – 12:30 Q & A
Moderator: Robert Settipane, MD
1:25 – 2:25 PBL: A 48-year-old man with chronic cough
Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD
William Corrao, MD, Dana Wallace, MD
2:25 – 2:40 Post-PBL wrap-up
Peter Dicpinigaitis, MD
2:40 – 3:10 Chronic cough and refractory chronic cough: An important distinction
Peter Dicpinigaitis, MD
3:10 – 3:15 Q & A
Adjourn
Sunday, September 24, 2023 8:15 - 10:30 am
Moderator: William Corrao, MD
8:15 – 8:40 New look at COPD: From phenotypes to novel targets for therapy
Nick Hanania, MD
8:40– 9:10 Non-cystic fibrosis bronchiectasis: New perspectives and new horizons
Anas Hadeh, MD
9:10 – 9:20 Q & A
9:20 – 9:50 Not every cough is asthma: Large airway disorders
Momen Wahidi, MD
9:50 – 10:20 The new frontier: Clinical consequences of long-COVID
Joseph Bellanti, MD
10:20 – 10:30 Q & A
Adjourn
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.
Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All identified relevant financial relationships with ineligible companies have been mitigated.
Antoine Azar, MD - Speaker
Advisor – Grifols, Takeda
Speaker – Grifols
Researcher – Grifols, X4
Consultant – Grifols, ArgenX
Don Bukstein, MD – Speaker
Speaker – Sanofi/Regeneron, AstraZeneca
Tom Casale, MD – Speaker
Speaker – Sanofi/Regeneron
Researcher – Sanofi/Regeneron, Genentech, Novartis, ARS, Jasper, HIH, PCORI, ALA
Consultant – Sanofi/Regeneron, Genentech, Novartis, ARS, Jasper
Mario Castro, MD – Speaker
Speaker – AstraZeneca, Sanofi, Genentech, TEVA, Regeneron, Amgen
Consultant – Novartis, Sanofi, Genentech, GSK, TEVA, Arrowhead Pharmaceuticals, Merck, Allakos, Amgen, OM Pharma, Pfizer, Pioneering Medicines
Independent Contractor – AstraZeneca, GSK, Novartis, Pulmatrix, Sanofi, Shionogi, Gala Therapeutics, Genentech, Theravance
William Corrao, MD – Planner, Moderator, Speaker
Speaker – GSK
Daniel Culver, MD – Speaker
Independent Contractor – Boehringer Ingelheim, Fibrogen, Pliant
Advisor - aTyr
Charles Daley, MD – Speaker
Advisor – AN2 Therapeutics, AstraZeneca, Hyfe, Insmed, Juvabis, MannKind, Matinas BioPharma Holdings, Paratek Pharmaceuticals, Spero Therapeutics, Zambon
Researcher – AN2 Therapeutics, Beyond Air, Bugworks, Insmed, Paratek Pharmaceuticals
Consultant – Cepheid, Genentech, Pfizer
Ray Davis, MD – Speaker
Consultant – TEVA, Takeda, Regeneron, Sanofi, Viiv
Peter Dicpinigaitis, MD – Speaker
Consultant – Bayer, Bellus, Chiesi, Shionogi, Trevi
Marilyn Glassberg, MD – Speaker
Advisory Board – Bellerophon Therapeutics, Boehringer Ingelheim, Roche/Genentech, Surrozen, Esperion, Bristol Myers Squibb
Independent Contractor – Roche/Genentech
Anas Hadeh, MD – Speaker
Advisor – Insmed, GSK, Merck
Consultant – Insmed
Speaker – Insmed, GSK
Nick Hanania, MD – Speaker
Speaker – Regeneron
Consultant – GlaxoSmithKline, AstraZeneca, Sanofi,
Independent Contractor – GlaxoSmithKline, AstraZeneca, Sanofi, Genentech
Advisor – Sanofi, AstraZeneca
Bruno Hochhegger, MD – Speaker
Consultant – Brainomix
Lisa Lancaster, MD – Speaker
Consultant – Roche, Boehringer Ingelheim, DevProBiopharma, Pieris, AstraZeneca, Oxygenium, Bellerphon, Senwha, Daewoong, Daiichi, Sankyo, Nashville Biosciences, Veracyte, United Therapeutics, Structure Therapeutics, Tvardi, Pure Tech, SynDevRx
Researcher – Roche, Pliant, Fibrogen, Novartis, Celgene, Galecto, BMS, Bridge Biotherapeutics, Horizon, CSL Behring, Nerre
Speaker – Boehringer Ingelheim, Veracyte, United Therapeutics, Genentech
Stocks - Tvardi
Jinesh Mahta, MD – Speaker
Speaker – United Therapeutics
Rey Panettieri, MD – Planner, Speaker, Moderator
Speaker – AstraZeneca, Sanofi, Merck & Co
Consultant – RIFM, AstraZeneca, Teva
Advisor – AstraZeneca, Genentech, RIFM, Praesidia Biotherapies
Independent Contractor – AstraZeneca, Teva, Medimmune, Activ-I, Janssen, Vault Health, RIFM, Novartis, AgoMab
Stephen Peters, MD – Speaker
Advisor – Syneos Health, Parexel, NIAID, PPD Development, Novartis Pharma, IQVIA
Lesley Saketkoo, MD – Speaker
Independent Contractor – ArgenX Pharmaceuticals, AbbVie, Janssen
Consultant – ArgenX Pharmaceuticals, AbbVie, Janssen, Boehringer Ingelheim, aTyr Pharmaceuticals, Corbus Pharmaceuticals
Advisor – AbbVie, Janssen
Speaker – AbbVie, Janssen, Boehringer Ingelheim
Researcher – AbbVie, Janssen, Boehringer Ingelheim, aTyr Pharmaceuticals, Kinevant Pharmaceuticals, Corium Pharmaceuticals, Corbus Pharmaceuticals, Kadmon Pharmaceuticals, Horizon, Beacon Pharmaceuticals
Robert Settipane, MD – Planner, Moderator
Independent Contractor – AstraZeneca, BioCryst, GSK, Regeneron, Teva, Celldex Therapeutics
Russell Settipane, MD – Planner, Reviewer, Moderator
Speaker – AbbVie, Amgen, AstraZeneca, BioCryst, Genentech, GlaxoSmithKline, Grifols, Pharming, Regeneron, Sanofi, Takeda, Boehringer Ingelheim
Advisory Board – AbbVie, Aimmune, Pfizer, AstraZeneca, BioCryst, Boehringer Ingelheim, Kalvista, Pharming, GlaxoSmithKline, DBV
Independent Contractor – AstraZeneca, GlaxoSmithKline, Teva, BioCryst, Regeneron, Celldex Therapeutics
Momen Wahidi, MD – Speaker
Consultant – Olympus, Cook Medical, Pulmonx, Veracyte
Dana Wallace, MD – Speaker
Speaker – Sanofi
Advisor - AbbVie, Bryn, Sanofi, ARS
The following have no relevant financial relationships with ineligible companies to disclose:
Joseph Bellanti, MD – Planner, Speaker
William Greisner III, MD – Planner, Moderator
James Klinger, MD – Speaker
Katelyn Loiselle, BSN, RN – Planner
Ginny Loiselle – Coordinator
Tiago Machuca, MD – Speaker
Richard Millman, MD – Speaker
Available Credit
- 16.25 AMA PRA Category 1 Credit™
- 16.25 Attendance
- 16.25 CBRN